Press Releases
Noramco Cannabinoids Business to Become Purisys
Noramco announced today that its industry-leading cannabinoids business will become a separate company – Purisys, LLC.
Noramco Presents Comments and Answers Questions at FDA Hearing on Cannabidiol
Noramco presented testimony and answered questions at the Food and Drug Administration’s (FDA) Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds, Part 15 Public Hearing.
Noramco and Willow Biosciences Announce Joint Development of Biosynthesis Platform for Cannabidiol
Noramco and Willow Biosciences Inc. today announced they have entered into an exclusive Joint Development Agreement (“JDA”) to collaboratively develop a yeast-based biosynthesis platform for the production and distribution of cannabidiol.
Nemus Bioscience Signs Agreement with Noramco
Nemus Bioscience announced an agreement with Noramco for the manufacturing and scale-up of proprietary analog of cannabidiol (CBD) licensed from the University of Mississippi.
Noramco welcomes enquiries from the news media.
Whether you are looking for basic company information or have a follow up question regarding a recent press release, we are here to help. During regular business hours (8:00AM-5:30PM EST, M-F) members of the media should call our corporate headquarters.
A major producer of specialty APIs for the pharmaceutical industry, Noramco is qualified to provide commentary in a number of topic areas, including API research and development, reference standards, and custom synthesis. For assistance, contact us.